Skip to main content

Peters William J's Form 4 filing

Amphastar Pharmaceuticals, Inc.AMPH · filed Mar 8, 2024

Accession no.
0001415889-24-007367
Filed
Mar 8, 2024
Trade date
Mar 6, 2024
Filing delay
2 days
Rule 10b5-1 plan
Checked

This filing lists 5 non-derivative transactions and 1 derivative transaction. Open-market sales total $843.0K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Peters William JCIK 0001263136Director, Officer (CFO, EVP & TREASURER)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Mar 6, 2024Common StockMOption exerciseAcquired+8,826$11.33+$99,998.58129,626Direct
Mar 6, 2024Common StockSSaleDisposed−13,404$46.30F2−$620,605.2116,222Direct
Mar 6, 2024Common StockSSaleDisposed−4,681$46.98F3−$219,913.38111,541Direct
Mar 6, 2024Common StockSSaleDisposed−51$48.00−$2,448111,490Direct
Mar 6, 2024Common StockFTax withholdingDisposed−2,190$46.31−$101,418.9109,300Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Mar 6, 2024Common StockMOption exerciseDisposed−8,826$0.00$00Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.79 to $46.78, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4.

Referenced by the price of 1 transaction in Table I.

F3

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.795 to $47.47, inclusive.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)